Innoviva, Inc. (INVA) Financial Statements (2023 and Earlier)

Company Profile

Business Address 1350 OLD BAYSHORE HIGHWAY
BURLINGAME, CA 94010
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance Sheet (Statement of Financial Position) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments202246 115129
Cash and cash equivalents202246 6273
Short-term investments   5256
Receivables11194 8371
Other undisclosed current assets12 11
Total current assets:314342 199200
Noncurrent Assets
Property, plant and equipment00 00
Long-term investments and receivables484438   
Long-term investments484438   
Deferred income tax assets1794 
Other noncurrent assets00 00
Deferred tax assets, net196 
Other undisclosed noncurrent assets111125 153167
Total noncurrent assets:613658 349167
TOTAL ASSETS:9261,000 548367
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities55 58
Accounts payable00 01
Employee-related liabilities10 02
Interest and dividends payable44 46
Other liabilities11 12
Other undisclosed current liabilities    25
Total current liabilities:66 635
Noncurrent Liabilities
Long-term debt and lease obligation395386 383574
Long-term debt, excluding current maturities395386 383574
Liabilities, other than long-term debt 0 11
Other liabilities 0 11
Total noncurrent liabilities:395386 383575
Total liabilities:400392 389610
Stockholders' equity
Stockholders' equity attributable to parent415540 154(243)
Common stock11 11
Treasury stock, value(394)   (3)
Additional paid in capital1,2641,261 1,2561,258
Accumulated other comprehensive loss   (0)(0)
Accumulated deficit(456)(722) (1,104)(1,499)
Stockholders' equity attributable to noncontrolling interest11168 50
Total stockholders' equity:526608 159(243)
TOTAL LIABILITIES AND EQUITY:9261,000 548367

Income Statement (P&L) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues392337 261217
Gross profit:392337 261217
Operating expenses(17)(16) (23)(34)
Operating income:375321 238184
Nonoperating income (expense)8751 (4)(6)
Investment income, nonoperating9152 21
Other nonoperating expense(4)(0) (6)(7)
Interest and debt expense(19)(18) (24)(44)
Income from continuing operations before equity method investments, income taxes:443354 210134
Other undisclosed income from continuing operations before income taxes2    
Income from continuing operations before income taxes:445354 210134
Income tax expense (benefit)(76)(60) 196 
Net income:369294 406134
Net loss attributable to noncontrolling interest(103)(69) (11)(0)
Net income available to common stockholders, basic:266224 395134
Interest on convertible debt55 66
Net income available to common stockholders, diluted:271229 401140

Comprehensive Income ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net income:369294 406134
Other undisclosed comprehensive income (loss) (0) 0(0)
Comprehensive income:369294 406134
Comprehensive loss, net of tax, attributable to noncontrolling interest(103)(69) (11)(0)
Comprehensive income, net of tax, attributable to parent:266224 395134

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: